Key Highlights

  • Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) traded at USD 1.55, up 9.15%, in pre-market trading on Wednesday, October 28, 2026, and no company-specific announcement dated on or just before that session has been identified.
  • A quarterly results summary for the period ended June 30, 2026 points to USD 35 million of licence revenue, while the cash balance, net loss and per-share figures are not part of the figures cited.
  • NYSE Regulation accepted the company's compliance plan, submitted on Thursday, June 18, 2026, and granted a plan period through Saturday, November 27, 2027, while the company remains out of compliance with two listing sections.
  • Two United States patents covering Actimab-A in solid tumours expire in October 2043, and the quote is a thin pre-market snapshot that can change before the 9:30 a.m. ET open.

What Lies Behind the Move

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM), a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer, traded at USD 1.55, up 9.15%, in the pre-market snapshot of Wednesday, October 28, 2026. That implies a prior close of about USD 1.42, by simple arithmetic on the quote. No company-specific announcement dated on or just before Wednesday, October 28, 2026 came with the move. The most recent company disclosure identified is a regulatory filing covering Actimab-A patent issuance, an additional manufacturer added to its investigational new drug application and the status of its exchange listing. The advance looks consistent with thin pre-market liquidity and sentiment toward radiopharmaceutical names, an inference rather than a confirmed cause. Pre-market quotes can change before the 9:30 a.m. ET open.

How the Pipeline and Listing Plan Frame the Move

A regulatory filing from Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) says that two United States patents on Actimab-A in solid tumours, which work by targeting myeloid-derived suppressor cells, run until October 2043. More patents are issued or pending in Canada, Europe, Japan and China, covering low peripheral blast acute myeloid leukaemia and combinations with venetoclax and CLAG-M. The investigational new drug application now lists an extra manufacturer to supply National Cancer Institute collaboration studies, and clinical milestones are due from the fourth quarter of 2026 into 2027. A results summary for the period ended June 30, 2026 mentions USD 35 million of licence revenue, which the cited material does not break down.

Downside Scenarios and Key Dates

Supporters point to a patent estate lasting to 2043, extra manufacturing capacity and clinical milestones due from the fourth quarter of 2026. Critics point to non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American company guide, which relate to stockholders' equity measured against losses, and to a regulatory setback for Iomab-B mentioned in a results summary. Risks include more equity financing, delisting if plan milestones are missed, trial timing and thin liquidity. Key dates and events: the Federal Reserve decision due later on Wednesday, October 28, 2026, third quarter results, clinical milestones from the fourth quarter of 2026 and progress on the compliance plan.

Where Things Stand

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) rose 9.15% before the open on Wednesday, October 28, 2026 with no dated company announcement, which fits thin liquidity and sentiment toward radiopharmaceutical names. The figure to anchor on is the plan period through Saturday, November 27, 2027, which NYSE Regulation granted for restoring listing compliance. Upcoming catalysts are the Federal Reserve decision later on Wednesday, October 28, 2026, the third quarter results and clinical milestones expected from the fourth quarter of 2026. Pre-market prices are snapshots and can change, and this is not investment advice.